VC
SYRE icon

VarCov Co’s Spyre Therapeutics SYRE Stock Holding History

VarCov Co’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$257K Buy
+2,895
New +$211K 0.1% 305
2026
Q1 		– Sell
-8,008
Closed -$262K – 621
2025
Q4 		$262K Buy
+8,008
New +$209K 0.1% 327

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

VarCov Co's SYRE Position: Q2 2026 in Review

VarCov Co opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 2,895 shares worth $257K. The stake represents 0.1% of the portfolio and ranks #305 among its holdings. This is a return to the name: VarCov Co previously reported a position in SYRE as recently as Q4 2025.

VarCov Co first reported a position in SYRE in Q4 2025 and has held it in 2 quarters since. The position peaked at $262K in Q4 2025. 263 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • VarCov Co held 2,895 shares of Spyre Therapeutics worth $257K as of Q2 2026.
  • Spyre Therapeutics was a new VarCov Co position in Q2 2026.
  • Spyre Therapeutics made up 0.1% of VarCov Co's portfolio in Q2 2026, its #305 holding.
  • VarCov Co first reported a position in Spyre Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • VarCov Co's Spyre Therapeutics position peaked at $262K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.